Table 2

Primary outcome measures used across randomised controlled trials for FND subgroups

FND symptoms	Primary outcome measures
Seizures (k=15)	Core symptoms Seizure frequency/occurrence (k=11)38–45 (S1 and S2) (Fobian NCT02801136).
	Life impact SF-36/QoLIE-31 (k=1) (Hingray NCT02311829). WSAS (k=1).45
	Other Treatment adherence/HCU (k=3) (S3 and S4) (Schommer NCT03329703).
Movement disorder (k=7)	Core symptoms PMDRS (k=4) or other FMD clinician rating scale (k=1) (S5–S9).
	CGI-I (clinician) (k=1) (S10).
	Other Unspecified (k=1) (S11).
Paralysis/weakness (k=4)	Core symptoms Subjective symptom severity ratings (k=1) (S12) or CGI-I (patient) (k=1) (Nicholson ISRCTN51225587). Clinician-rated symptom severity (Chastan NCT01352910).
	Dynamometry (k=1) (S13).
	Life impact Disability (SF-12, MRS, k=1) (S12).
Mixed motor symptoms (k=4)	Core symptoms CGI-I (k=1) (Koning-Tijssen NCT02589886).
	Life impact SF-36 Physical Functioning Scale (k=1) (S14).
	Other Unspecified (k=1) (S15).
Other mixed symptoms (k=10)	Core symptoms Clinician-rated symptom severity (k=3) (S16–S18)
	CGI-I (k=2, 1=clinician, 1=patient) (S19 and S20).
	SDQ-20 (k=1) (S19).
	Recovery (unspecified, k=1) (S21).
	Life impact SF-36 (k=1) (S22).
	MRS (k=1) (S19).
	Other Treatment adherence/HCU (k=1) (Bullock NCT02764476). Interoception/attention tasks (k=1) (S23).

References S1-S23 are available in Supplementary File 7
CGI-I, Clinical Global Impression–Improvement; FMD, functional movement disorder; FND, functional neurological disorder; HCU, healthcare use; k, number of studies; MRS, Modified Rankin Scale; PMDRS, Psychogenic Movement Disorder Rating Scale; QoLIE-31, Quality of Life In Epilepsy-31; SDQ-20, Somatoform Dissociation Questionnaire-20 item; SF-12, 12-Item Short Form Health Survey; SF-36, 36-Item Short Form Health Survey; WSAS, Work and Social Adjustment Scale.